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Exhaled nitric oxide has previously been found to be low in cystic fibrosis. The aim of this study was to determine whether exhaled nitric
oxide levels would increase in response to oral l-arginine supplementation administered daily for 4 weeks. Exhaled and nasal nitric oxide
was measured weekly. Plasma l-arginine levels increased in response to supplementation but this was not reflected in an increase in eNO
levels.
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A number of studies have indicated that levels of
exhaled and nasal nitric oxide (NO) are low in patients
with cystic fibrosis (CF) [1]. However, the mechanism(s)
underlying this observation and the impact, if any, of
reduced airways NO are unclear. Possible reasons for low
measured levels of exhaled and nasal NO include a primary
reduction in ability to synthesis NO; trapping of NO in
mucus with subsequent conversion to nitrate and nitrite;
impairment of NO synthesis as a consequence of chronic
inflammation; pancreatic insufficiency leading to low levels
of l-arginine; and possible consumption of NO by the
denitrifying organism Pseudomonas aeruginosa, which
utilises the enzyme NO reductase. A recent study found
that nitric oxide levels, and its metabolites, were no
different in young CF patients when compared to controls,
and suggested that decreased NOS II expression occurs with
increasing airway inflammation [2].
Nitric oxide is produced in the airways from oxidation of
l-arginine via nitric oxide synthases (NOS), of which there
are three isoforms. It has a number of important functions
including vasodilation, bronchodilation, modulation of
ciliary activity, and enhancement of neutrophil migration,1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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response [3]. Impairment of NO synthesis may therefore
have implications for the progression of the disease. Further
evidence to support the suggestion that NO levels in the
airway may have an impact on disease progression comes
from the suggestion that nitric oxide synthase 1 (NOS1)
may act as a bmodifierQ gene in patients with cystic fibrosis.
The proximal region of the NOS1 gene contains dinucleo-
tide GT repeats. It has recently been shown that patients
with more than 27 repeats in this region have a lower annual
FEV1 loss [4]. This implies an association between the
NOS1 gene locus and the progression of lung disease in CF,
which is independent of the CFTR genotype. A previous
study showed that CF patients with a higher number of
repeats in the NOS1 gene had lower exhaled nitric oxide
levels [5], and this may provide the link between the
genotype and disease progression. If this is the case, it is
possible that increasing airway nitric oxide levels could be
of therapeutic benefit for cystic fibrosis patients.
l-arginine is an essential amino acid with a short half-life
due to rapid metabolism. It is used therapeutically to treat
certain metabolic diseases. A number of studies suggest that
levels of NO in the airways may rise in response to
administration of l-arginine. Nasally inhaled nebulised l-
arginine has been shown to increase nasal nitric oxide levels
and decrease nasal mucociliary clearance time in patients
with primary ciliary dyskinesia (PCD) [6]. It has also been
shown to increase exhaled nitric oxide levels in asthmatics 4 (2005) 67–69ed by Elsevier B.V. All rights reserved.
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patients with CF, levels of exhaled and nasal NO increased
in response to l-arginine administered by infusion, although
subnormal throughout [9]. Pulmonary function tests were
unchanged.
The aim of this pilot study was to determine whether oral
supplementation of l-arginine administered daily for 1
month would result in increased plasma levels and whether
this would be reflected in increased levels of eNO and nNO
in patients with CF.week number
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b2. Method
Six patients with cystic fibrosis aged 6–16 years of age
were recruited. Patients were seen weekly for a total of six
visits. At each visit, they had FEV1 and FVC measured,
along with measurements of exhaled and nasal nitric oxide.
Exhaled and nasal nitric oxide levels were measured via a
chemiluminescence analyser (LR2500; Logan Research,
Kent, UK), in accordance with published recommended
standards for cooperative children [10,11]. Exhaled levels
were recorded at flow rates of 50 ml/s. Three attempts
were allowed at each rate and the mean was calculated. All
nitric oxide levels were taken within 1 h of ingestion of
l-arginine.
Oral l-arginine was commenced on week 2 and
continued for 4 weeks. A dose of 150 mg/kg/day was
administered in three divided doses, as advised by our
metabolic department. Amino acid levels were taken at
baseline, week 3, and week 6.
Ethical approval was obtained prior to the onset of this
study.Fig. 1. (a) Exhaled nitric oxide at 50 ml/s. (b) Nasal nitric oxide.3. Results
The recruited patients included three boys and three girls
(mean age 12.9 years; range 6.16–15.4 years). All, but one,
were homozygous for the delta F508 mutation and all had
been colonised with non-mucoid Pseudomonas for more
than a year prior to entry into the study. One patient
withdrew at visit 5 due to an infective exacerbation. One
patient declined to have amino acid levels checked at visit 3.
The mean plasma l-arginine level at entry to the study
was 57 Amol/L (range 43–99 Amol/L), lying within the
normal range (0–150 Amol/L). While on supplements, l-
arginine levels increased significantly with a mean value at
visit 3 of 154 Amol/L (range 36–294 Amol/L) and 174 Amol/
L (range 78–262 Amol/L) at visit 6.
No side effects or adverse events were noted and there
was no increase in the number of infective exacerbations
during the 12 months following treatment.
Despite increases in plasma l-arginine levels, there was
no evidence of a significant impact on either exhaled or
nasal nitric oxide levels (Fig. 1a and b).Lung function varied between patients but, for each
patient, both FEV1 and FVC remained unchanged through-
out the study.4. Conclusion
Oral supplementation resulted in an increase in plasma
levels of l-arginine, the essential substrate for the produc-
tion of nitric oxide, but this was not reflected in increased
eNO levels. This would suggest that lack of substrate is not
a major factor and that providing increased substrate does
not overcome the mechanism contributing to the relatively
low levels of eNO and nNO observed in patients with cystic
fibrosis. It remains possible that a higher dose of l-arginine
may have been necessary to increase eNO levels. However,
plasma l-arginine levels were in excess of the normal range
in half of the samples obtained on supplementation,
suggesting that higher doses would not have had a greater
impact.
M.L. Everard, D. Donnelly / Journal of Cystic Fibrosis 4 (2005) 67–69 69Oral arginine was well tolerated by our patients. One
possible adverse effect of supplementation may be to
promote the growth of P. aeruginosa, which utilizes
arginine. However, in this small pilot study, we were
unable to identify any evidence that l-arginine may
adversely affect the clinical status of patients colonised
with Pseudomonas.
Despite increased circulating levels of plasma l-arginine,
we were unable to identify a significant increase in exhaled
NO levels. It therefore seems unlikely that significant
therapeutic benefits would be derived from l-arginine
supplementation in patients with cystic fibrosis.References
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